Findings Could Lead to Early Diagnosis, Better Treatment Studies
An ultrasensitive test has been developed that detects a corrupted protein associated with Alzheimer’s disease and chronic traumatic encephalopathy (CTE), a condition found in athletes, military veterans, and others with a history of repetitive brain trauma. This advance could lead to early diagnosis of these conditions and open new research into how they originate, according to National Institutes of Health scientists and their colleagues. In their new study, published in Acta Neuropathologica, the researchers explain how they adapted a diagnostic test originally developed for prion diseases to detect abnormal clusters of tau protein. Like other proteins involved in neurological diseases, tau protein clusters can seed themselves and contribute substantially to the disease processes of Alzheimer’s and CTE. The study involved brain samples from 16 Alzheimer’s patients, two boxers with CTE, and numerous control cases involving other brain diseases.
The test is extremely sensitive. For example, if a pinhead-sized sample of brain tissue from an Alzheimer’s patient were pulverized and diluted into a thousand gallons of liquid, the test still could detect tau seeds in a pinhead-sized volume of that dilution. The test is called AD RT-QuIC: Alzheimer’s disease real-time quaking induced conversion.
Scientists at NIH’s National Institute of Allergy and Infectious Diseases developed RT-QuIC about a decade ago to detect Creutzfeldt-Jakob (CJD) and other prion diseases. Since then, they have repeatedly improved and adapted it to detect other neurological diseases, such as Parkinson’s and dementia with Lewy bodies. The test, which already is used in clinical settings to diagnose sporadic CJD, is noted for its rapid and accurate results.
Their latest findings could be a major advance for Alzheimer’s diagnostics because the study points to tau seeds as potential biological “markers” for Alzheimer’s disease in the brain. Scientists are testing therapies to slow the accumulation of tau clusters and the progression of neurological disease. In these efforts, they need more sensitive and accurate tests to better select clinical trial participants and assess whether new therapeutic strategies work as hoped.
Alzheimer’s affects about 5.7 million people in the United States alone at an estimated annual cost of $232 billion, according to the Alzheimer’s Association.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Eli Lilly Has Good News About Its Alzheimer’s Drug. Here’s What It Means for Biogen.on January 12, 2021 at 5:10 pm
Eli Lilly’s optimistic results for its Alzheimer’s drug in a clinical trial is a good sign for rival Biogen, which is looking for its similar drug to be approved.
- Alzheimer's Progression Tracks With Blood Biomarkerson January 12, 2021 at 3:11 pm
Blood-based biomarkers paralleled the progression of Alzheimer's disease neurodegeneration, a large longitudinal cohort study showed. Increases of phosphorylated tau at threonine 181 (p-tau181) in ...
- SEC takes enforcement action against IGC for claims made about cannabis-based treatment for Alzheimer’s symptomson January 12, 2021 at 9:42 am
The Securities and Exchange Commission has imposed a cease-and-desist order against India Globalization Capital and its founder and chief executive ...
- Full interview with Eli Lilly CEO David Ricks on Alzheimer's data, Covid treatmenton January 12, 2021 at 2:56 am
Eli Lilly CEO David Ricks joined CNBC's Meg Tirrell on "Squawk Box" to discuss the company's latest positive data on its Alzheimer's treatment as well as the latest on the company's Covid antibody ...
- Biogen gets stock bump on Eli Lilly Alzheimer’s newson January 11, 2021 at 5:53 pm
Biogen added more than $4 billion in market value on Monday after a rival Alzheimer’s disease treatment from Eli Lilly showed promise in a small clinical trial. The preliminary benefit of Lilly’s ...
- Lilly Alzheimer's drug slows mental, functional decline in mid-stage trial, shares jumpon January 11, 2021 at 3:28 pm
Eli Lilly and Co said on Monday a small trial of its experimental Alzheimer's drug found that it slowed by about a third the rate of decline in a combined measure of cognition and function in patients ...
- Lilly’s Alzheimer's Drug Isn’t Worth $20 Billion Yeton January 11, 2021 at 11:21 am
This was a surprise and investors cheered the news, sending Lilly’s shares up more than 11% and adding almost $20 billion to the company’s market value. Shares of Biogen Inc., which is working on an ...
- Lilly says Alzheimer's drug slows clinical decline in mid-stage trialon January 11, 2021 at 8:47 am
Eli Lilly and Co said on Monday a trial of its experimental Alzheimer's drug donanemab showed it slowed by about a third the rate of decline in a combined measure of cognition and function in ...
- Lilly’s Alzheimer’s News Brings Plenty of Upside, Limited Riskon January 11, 2021 at 8:34 am
Betting that this time is different for a promising Alzheimer’s disease treatment is a fairly inexpensive wager.
- Alzheimer’s Drug Shows Promise in Small Trialon January 11, 2021 at 8:10 am
Participants with the disease still declined, but much more slowly than those receiving a placebo, investigators say.
via Bing News